Cidara: Potential To Change Flu Prophylaxis Landscape With CD388
Portfolio Pulse from
Cidara Therapeutics is developing CD388, a potential game-changer in flu prophylaxis, with results from a phase 2b study expected in Q3 2025. CD388 could revolutionize flu treatment by offering broad coverage against influenza A and B, even in immunocompromised patients.
November 21, 2024 | 8:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cidara Therapeutics is developing CD388, a potential breakthrough in flu prophylaxis, with phase 2b results expected in Q3 2025. This could significantly impact the company's stock if successful.
The development of CD388 by Cidara Therapeutics represents a significant advancement in flu prophylaxis, potentially offering broad coverage against influenza A and B. The anticipation of phase 2b results in Q3 2025 could drive investor interest and positively impact the stock price if results are favorable.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100